Related Experiment Video
Updated: Mar 25, 2026
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.6K
Development and partial characterization of fused human endostatin
J Anakha1, Yenisetti Rajendra Prasad1, Sanjay Chakka2
1Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, (Mohali), 160062, Punjab, India.
Protein Expression and Purification
|March 23, 2026
Summary
Engineered fused human endostatin (FHE) shows potent anti-angiogenic activity, maintaining endostatin’s efficacy. This fusion protein demonstrates potential for therapeutic development against angiogenesis-driven diseases.
Area of Science:
- Biotechnology
- Molecular Biology
- Drug Development
Background:
- Angiogenesis is crucial in pathological conditions, making its inhibition a therapeutic target.
- Endostatin is a potent natural angiogenesis inhibitor but faces clinical limitations like instability.
- Fusion protein engineering offers a strategy to improve the therapeutic potential of bioactive proteins.
Purpose of the Study:
- To design, produce, and characterize a fused human endostatin (FHE) molecule.
- To evaluate the in vitro and in vivo biological activity of FHE.
- To assess FHE's potential as an anti-angiogenic therapeutic agent.
Main Methods:
- FHE was created by fusing recombinant human endostatin (rhEs) with a transferrin fragment via a peptide linker.
- The Pichia pastoris expression system was used for protein production.
- Biological activity was assessed using human retinal microvascular endothelial cell (HRMEC) proliferation assays and the chick chorioallantoic membrane (CAM) assay.
Main Results:
- FHE exhibited potent, dose- and time-dependent inhibition of HRMEC proliferation, showing endothelial-specific activity.
- No anti-proliferative effect was observed on A549 non-endothelial tumor cells, confirming target specificity.
- In vivo CAM assays demonstrated significant, dose-dependent anti-angiogenic activity comparable to native rhEs.
Conclusions:
- The FHE fusion protein preserves endostatin's anti-angiogenic biological activity.
- FHE maintains specificity for angiogenic processes.
- FHE shows promise for further preclinical and therapeutic development as an anti-angiogenic agent.
